Keywords: Bayer, Johnson & Johnson, Xarelto, Janssen, USA, FDA, Stroke prevention

US FDA clears Bayer/Johnson & Johnson’s Xarelto for stroke risk reduction in AF patients

Article | 07 November 2011

Print This

In what was much-awaited good news for German drug major Bayer (BAY: DE), its US subsidiary announced late Friday (November 4) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in